A Multicenter Study on Atrioventricular Regurgitation in Transthyretin Amyloid Cardiomyopathy: Definition, Prevalence, and Prognostic Impact.

Launched by MEDICAL UNIVERSITY OF VIENNA · Feb 14, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how common certain heart problems, specifically mitral and tricuspid regurgitation, are in patients who have a condition called transthyretin amyloid cardiomyopathy (ATTR-CM). Mitral and tricuspid regurgitation occur when the heart's valves do not close properly, causing blood to flow backward. The researchers aim to better understand these issues, develop new ways to measure their severity, and see how they affect patients' overall health.

To participate in this study, you need to be at least 18 years old and have a confirmed diagnosis of ATTR-CM. You should also have had an echocardiogram (a test that uses sound waves to create images of your heart) done within the last six months. The study is currently recruiting participants, and if you join, you can expect to undergo some heart assessments and provide your perspective on your health. This trial is important because it seeks to improve how we understand and treat heart problems related to ATTR-CM, which can be quite unique compared to other heart conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of ATTR-CM according to current diagnostic criteria
• • Comprehensive baseline echocardiographic assessment, including (semi-)quantitative mitral and tricuspid regurgitation (MR/TR) parameters, performed within ±6 months of diagnosis
• • Age ≥ 18 years
• • Willingness to participate in the study and provide informed consent
• Exclusion Criteria:
• • Severe aortic valve disease requiring intervention
• • Inability to provide informed consent or participate in study follow-up